OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
By Jose Antonio Lanz, Decrypt
Picture: Decrypt
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
Also carried by The Information, PharmTech.com, Dealroom.
This report was first published by Decrypt. What you see here is a brief excerpt. The full text is theirs.
Continue reading at Decrypt
